Recent publications published by researchers at the MRC WIMM.
Genome-Wide Association Studies of Down Syndrome Associated Congenital Heart Defects Suggests a Genetically Heterogeneous Risk for CHD in DS.
Feldman ER. et al, (2025), Genet Epidemiol, 49
A Revised Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse.
Van Der Maas NG. et al, (2025), Blood Adv
Clonal tracing with somatic epimutations reveals dynamics of blood ageing.
Scherer M. et al, (2025), Nature
Protocol for high-quality RNA sequencing, cell surface protein analysis, and genotyping in single cells using TARGET-seq.
Jakobsen NA. et al, (2025), STAR Protoc, 6
Genome-wide association study of somatic GATA1s mutations in newborns with Down Syndrome.
Li Y. et al, (2025), Blood Adv
Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation.
Hosseini A. et al, (2025), Nature
Microbial metabolite drives ageing-related clonal haematopoiesis via ALPK1.
Agarwal P. et al, (2025), Nature
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 study.
Zeidner JF. et al, (2025), Blood
Risk Stratification in Older Intensively Treated Patients With AML.
Versluis J. et al, (2024), J Clin Oncol, 42, 4084 - 4094
Genome-wide association studies of Down syndrome associated congenital heart defects.
Feldman ER. et al, (2024)
Hematopoietic stem cell heterogeneity and age-associated platelet bias are evolutionarily conserved.
Aksöz M. et al, (2024), Sci Immunol, 9
Selective advantage of mutant stem cells in human clonal hematopoiesis is associated with attenuated response to inflammation and aging.
Jakobsen NA. et al, (2024), Cell Stem Cell, 31, 1127 - 1144.e17
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia.
Cogswell TJ. et al, (2024), RSC Med Chem, 15, 3495 - 3506
Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
Risueño A. et al, (2024), Leuk Res, 140
Real-world Effectiveness of Azacitidine in Treatment-Naive Patients With Higher-risk Myelodysplastic Syndromes.
Rajakumaraswamy N. et al, (2024), Clin Lymphoma Myeloma Leuk, 24, 260 - 268.e2